Sionna Therapeutics is trading 5.1% down at $6.82, with no fresh company-specific announcement identified for September 18, 2026; the immediate decline’s catalyst remains unclear.
- Recent restructuring remains an overhang: a 46% workforce reduction and discontinuation of SION-719 development as an add-on treatment.
- Sionna expects approximately $6.4 million in related charges.
- The announcements came earlier in the week, while biotechnology broadly is strengthening.